Featured Research

from universities, journals, and other organizations

Information About Use And Accuracy Of Breast Cancer Tests Is Lacking, Study Finds

Date:
September 14, 2009
Source:
American Cancer Society
Summary:
A new study finds that there is little information available about the use of new testing technologies and targeted therapies in breast cancer, specifically the anti-cancer drug trastuzumab (Herceptin).

A new study finds that there is little information available about the use of new testing technologies and targeted therapies in breast cancer, specifically the anti-cancer drug trastuzumab (Herceptin).

Published in the November 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the review suggests that many breast cancer patients who may benefit from trastuzumab are not receiving it, and that some women receiving the drug have never been tested for the receptor it targets.

Standard care now dictates that women with early-stage breast cancer should be tested to see if they have tumors that express the HER2 protein. Those who test positive are candidates for treatment with trastuzumab, which is only effective in HER2-positive cancers.

Researchers at the UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS) and led by Kathryn A. Phillips, PhD, of the University of California-San Francisco, reviewed the medical literature to determine how HER2 testing is being used in routine clinical practice. The studies they found reported that up to two-thirds of patients eligible for HER2 testing had no documentation of a test in their health insurance records. About one in five women who received trastuzumab had no documentation of a positive HER2 test in their health insurance records. The studies also revealed that about one in five HER2 test results may be incorrect.

The authors also found that studies looking at the economic issues associated with prescribing trastuzumab often did not explicitly consider the role of HER2 testing, which can have a substantial impact on the cost-effectiveness of the therapy.

Given the increasing use of targeted therapies like trastuzumab, proper testing will become more important to ensure that medications are directed only to the patients who will benefit from them.

"Our review of the literature suggests that there are important knowledge gaps regarding the real-world use of HER2 testing and trastuzumab," said Dr. Elena Elkin, a researcher at Memorial Sloan-Kettering Cancer Center in New York and one of the study's authors. "Filling these gaps may help optimize limited health care resources and improve care for women with breast cancer," she added.


Story Source:

The above story is based on materials provided by American Cancer Society. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kathryn A. Phillips, Deborah A. Marshall, Jennifer S. Haas, Elena B. Elkin, Su-Ying Liang, Michael J. Hassett, Ilia Ferrusi, Jane E. Brock, and Stephanie L Van Bebber. Clinical practice patterns and cost-effectiveness of HER2 testing strategies in breast cancer patients. Cancer, 2009; DOI: 10.1002/cncr.24574

Cite This Page:

American Cancer Society. "Information About Use And Accuracy Of Breast Cancer Tests Is Lacking, Study Finds." ScienceDaily. ScienceDaily, 14 September 2009. <www.sciencedaily.com/releases/2009/09/090914110526.htm>.
American Cancer Society. (2009, September 14). Information About Use And Accuracy Of Breast Cancer Tests Is Lacking, Study Finds. ScienceDaily. Retrieved September 3, 2014 from www.sciencedaily.com/releases/2009/09/090914110526.htm
American Cancer Society. "Information About Use And Accuracy Of Breast Cancer Tests Is Lacking, Study Finds." ScienceDaily. www.sciencedaily.com/releases/2009/09/090914110526.htm (accessed September 3, 2014).

Share This



More Health & Medicine News

Wednesday, September 3, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins